Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqCM:APPS
NasdaqCM:APPSSoftware

Why Digital Turbine (APPS) Is Down 7.0% After Raising 2026 Revenue Guidance And Returning To Profitability

In early February 2026, Digital Turbine, Inc. reported third-quarter 2025 results showing sales rising to US$151.4 million and a shift from a net loss to a net income of US$5.11 million, while also completing a roughly US$58.57 million at-the-market follow-on equity offering. The company additionally raised its 2026 revenue guidance to a range of US$553 million to US$558 million, signaling management’s increased confidence after a year-to-date improvement in profitability and a reduced...
NYSE:AZZ
NYSE:AZZBuilding

Assessing AZZ (AZZ) Valuation After A Strong Multi Year Share Price Run

AZZ stock: recent performance snapshot AZZ (AZZ) has drawn fresh attention after a strong run in recent months, with total return around 41% over the past year and roughly 2.5x over three years. See our latest analysis for AZZ. With the share price at US$137.46 and a 90-day share price return of 40.78%, recent momentum has been strong and complements AZZ’s 43.04% 1-year total shareholder return and 252.73% 3-year total shareholder return. If AZZ’s strong run has you thinking about what else...
NYSE:PCG
NYSE:PCGElectric Utilities

PG&E (PCG) Is Up 5.4% After Modest 2025 Earnings Uptick Has The Bull Case Changed?

PG&E Corporation has released its full-year 2025 results, reporting US$24,935 million in revenue and US$2,593 million in net income, both slightly higher than the prior year. The modest increase in earnings per share from continuing operations, with diluted EPS rising to US$1.18, may be particularly relevant for investors monitoring PG&E's post-bankruptcy recovery and risk profile. Next, we’ll explore how this incremental earnings growth and revenue improvement influences PG&E’s broader...
XTRA:DB1
XTRA:DB1Capital Markets

Assessing Deutsche Börse (XTRA:DB1) Valuation After Mixed 2025 Earnings And Share Price Reaction

Deutsche Börse (XTRA:DB1) is back in focus after reporting fourth quarter and full year 2025 earnings, with higher sales alongside mixed net income trends that give investors fresh numbers to reassess the stock. See our latest analysis for Deutsche Börse. The earnings release appears to have shifted sentiment in the short term, with a 1-day share price return of 3.05% taking Deutsche Börse to €209.5. This comes even though the year-to-date share price return is a 4.29% decline and the 1-year...
LSE:BATS
LSE:BATSTobacco

British American Tobacco Extends Chair Tenure As Succession And Strategy Evolve

British American Tobacco has extended Chair Luc Jobin’s tenure beyond the UK Corporate Governance Code’s recommended nine year limit. Karen Guerra has been appointed as Senior Independent Director, while Holly Keller Koeppel is set to step down from the board at the next AGM. These changes come as the board oversees British American Tobacco’s ongoing transformation and capital allocation priorities. For investors following LSE:BATS, these governance moves come at a time when the shares...
NYSE:MCO
NYSE:MCOCapital Markets

Moody’s UAE Bank Upgrade Puts Emerging Market Focus In Investor View

Moody's (NYSE:MCO) has upgraded its outlook for UAE banks to positive. The outlook change reflects trends in economic diversification and reforms in the region. The move highlights Moody's active focus on key emerging markets that attract global investor interest. For investors watching Moody's at a share price of $412.23, this UAE banking outlook shift illustrates how the company is closely tracking structural changes in important regions. The stock has recorded a 36.2% return over 3 years...
SEHK:6855
SEHK:6855Biotechs

Ascentage China IND Clearance Puts BTK Degrader On Global Cancer Track

Ascentage Pharma Group International (SEHK:6855) received investigational new drug clearance in China for APG-3288, its next generation BTK targeted protein degrader. The Chinese clearance follows earlier U.S. FDA approval for clinical testing, aligning the program across two major drug development markets. APG-3288 is being developed for treatment resistant blood cancers, with a focus on hematologic malignancies that do not respond to existing BTK therapies. For investors tracking oncology...